

## CORRECTION

## Author Correction: Apolipoprotein C1 promotes glioblastoma tumorigenesis by reducing KEAP1/NRF2 and CBS-regulated ferroptosis

Xiang-jin Zheng<sup>1,2</sup>, Wen-lin Chen<sup>3</sup>, Jie Yi<sup>4</sup>, Wan Li<sup>1,2</sup>, Jin-yi Liu<sup>1,2</sup>, Wei-qi Fu<sup>1,2</sup>, Li-wen Ren<sup>1,2</sup>, Sha Li<sup>1,2</sup>, Bin-bin Ge<sup>1,2</sup>, Yi-hui Yang<sup>1,2</sup>, Yi-zhi Zhang<sup>1,2</sup>, Hong Yang<sup>1,2</sup>, Guan-hua Du<sup>1,2</sup>, Yu Wang<sup>3 ⋈</sup> and Jin-hua Wang<sup>1,2 ⋈</sup>

Acta Pharmacologica Sinica (2024) 45:2226-2227; https://doi.org/10.1038/s41401-024-01271-2

Correction to: Acta Pharmacologica Sinica https://doi.org/10.1038/s41401-022-00917-3, published online 17 May 2022

The authors are very sorry for the inadvertent mistake in the Figure 4: the images of intracellular Fe<sup>2+</sup> in Erastin-induced ferroptosis of NQO1 (siNQO1-1-Erastin, siNQO1-1-Erastin+Fer-1) in Fig. 4e were provided incorrectly. In addition, by checking the experimental data, we found that the images of NQO1 group in Fig. 4e (siNQO1-1, siNQO1-2-Erastin+Fer-1) were used

incorrectly. The images of NQO1 group in Fig. 4e were used wrongly due to our carelessness during the stage of figure preparation. We have checked and replaced the wrong images with correct images in siNQO1-1, siNQO1-1-Erastin+Fer-1 and siNQO1-2-Erastin+Fer-1 in Fig. 4e. The conclusion of the original article or the context of the article was not affected. The corrected figures are presented as follows. The authors apologize for any inconvenience caused to the journal and readers.


 $Correspondence: Yu\ Wang\ (ywang@pumch.cn)\ or\ Jin-hua\ Wang\ (wjh@imm.ac.cn)$ 

These authors contributed equally: Xiang-jin Zheng, Wen-lin Chen

Published online: 13 May 2024

<sup>&</sup>lt;sup>1</sup>The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing 100050, China; <sup>2</sup>Key Laboratory of Drug Target Research and Drug Screen, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China; <sup>3</sup>Department of Neurosurgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China and <sup>4</sup>Department of Clinical Laboratory, Peking Union Medical College Hospital, Beijing 100730, China





**Fig. 4 Knockdown of APOC1 promoted ferroptosis by reduced expression of HO-1 and NQO1 expression.** a Overexpression of APOC1 attenuated ROS level that can be reversed by knockdown of HO-1 and NQO1 expression in U251 cells. **b** mRNA expression of HO-1 and NQO1 was increased in U87 cells after treatment of Erastin for 24 h. **c** Knockdown of APOC1 expression decreased HO-1 and NQO1 mRNA level in U87 cells treated by Erastin for 24 h. **d** Knockdown of HO-1 or NQO1 expression increased ROS level of U87 cells treated by Erastin for 24 h. **e** Knockdown of HO-1 or NQO1 increased intracellular Fe<sup>2+</sup> of U251 cells in Erastin-induced ferroptosis. Representative images of Fe<sup>2+</sup> with identical results in three assays were shown. Scale bar =  $50 \, \mu m$ . **f** Knockdown of HO-1 or NQO1 increased lipid ROS level of U87 cells. Experiments were performed in triplicate. Data are presented as mean  $\pm$  SD (n = 3). Statistical significance was determined by Student's t test or one-way ANOVA, \*\*P < 0.01, \*\*\*P < 0.001 vs. NC.